These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16178757)

  • 21. [Antagonists of ionotropic glutamate receptors as the object of research in psychopharmacology].
    Bespalov AIu; Evartau EE
    Usp Fiziol Nauk; 1999; 30(1):39-53. PubMed ID: 10205818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain.
    Wu LJ; Zhuo M
    Neurotherapeutics; 2009 Oct; 6(4):693-702. PubMed ID: 19789073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Competitive Gly/NMDA receptor antagonists.
    Catarzi D; Colotta V; Varano F
    Curr Top Med Chem; 2006; 6(8):809-21. PubMed ID: 16719819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of glycine site NMDA receptor antagonists to protect against L-2-chloropropionic acid-induced neurotoxicity highlights the uniqueness of cerebellar NMDA receptors.
    Widdowson PS; Gyte AJ; Upton R; Wyatt I
    Brain Res; 1996 Nov; 738(2):236-42. PubMed ID: 8955518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents--toward an understanding of their favorable tolerability.
    Rogawski MA
    Amino Acids; 2000; 19(1):133-49. PubMed ID: 11026482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NMDA receptor antagonists for the treatment of neuropathic pain.
    Collins S; Sigtermans MJ; Dahan A; Zuurmond WW; Perez RS
    Pain Med; 2010 Nov; 11(11):1726-42. PubMed ID: 21044263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of norketamine enantiomers in rodent models of persistent pain.
    Holtman JR; Crooks PA; Johnson-Hardy JK; Hojomat M; Kleven M; Wala EP
    Pharmacol Biochem Behav; 2008 Oct; 90(4):676-85. PubMed ID: 18586315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonselective and NR2B-selective N-methyl-D-aspartic acid receptor antagonists produce antinociception and long-term relief of allodynia in acute and neuropathic pain.
    Swartjes M; Morariu A; Niesters M; Aarts L; Dahan A
    Anesthesiology; 2011 Jul; 115(1):165-74. PubMed ID: 21606828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NMDA receptor antagonists as analgesics: focus on the NR2B subtype.
    Chizh BA; Headley PM; Tzschentke TM
    Trends Pharmacol Sci; 2001 Dec; 22(12):636-42. PubMed ID: 11730974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of N-methyl-D-aspartate receptor antagonists on acute morphine-induced and l-methadone-induced antinociception in mice.
    Fischer BD; Carrigan KA; Dykstra LA
    J Pain; 2005 Jul; 6(7):425-33. PubMed ID: 15993820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deletion of the C-terminal domain of the NR2B subunit alters channel properties and synaptic targeting of N-methyl-D-aspartate receptors in nascent neocortical synapses.
    Mohrmann R; Köhr G; Hatt H; Sprengel R; Gottmann K
    J Neurosci Res; 2002 May; 68(3):265-75. PubMed ID: 12111856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain.
    Siu A; Drachtman R
    CNS Drug Rev; 2007; 13(1):96-106. PubMed ID: 17461892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on NMDA receptor-mediated EPSCs.
    Barton ME; White HS; Wilcox KS
    Epilepsy Res; 2004 Mar; 59(1):13-24. PubMed ID: 15135163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the noncompetitive N-methyl-d-aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats.
    Hillhouse TM; Negus SS
    Eur J Pain; 2016 Sep; 20(8):1229-40. PubMed ID: 26914635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycine/NMDA receptor antagonists as potential CNS therapeutic agents: ACEA-1021 and related compounds.
    Cai SX
    Curr Top Med Chem; 2006; 6(7):651-62. PubMed ID: 16719807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition.
    Spooren W; Mombereau C; Maco M; Gill R; Kemp JA; Ozmen L; Nakanishi S; Higgins GA
    Psychopharmacology (Berl); 2004 Aug; 175(1):99-105. PubMed ID: 14985927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [NMDA-receptor antagonist in pain therapy].
    Weber C
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Aug; 33(8):475-83. PubMed ID: 9746842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action.
    Kleckner NW; Glazewski JC; Chen CC; Moscrip TD
    J Pharmacol Exp Ther; 1999 May; 289(2):886-94. PubMed ID: 10215667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model.
    Nakazato E; Kato A; Watanabe S
    Pharmacology; 2005 Jan; 73(1):8-14. PubMed ID: 15452358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain.
    Qu XX; Cai J; Li MJ; Chi YN; Liao FF; Liu FY; Wan Y; Han JS; Xing GG
    Exp Neurol; 2009 Feb; 215(2):298-307. PubMed ID: 19046970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.